Business
TRULANCE® (plecanatide tablets) for Irritable Bowel Syndrome with Constipation in Adults is now Available to Canadians to Help Meet Treatment Gap that leaves 70 Per cent of Patients Unsatisfied(1)
TRULANCE® (plecanatide tablets) for Irritable Bowel Syndrome with Constipation in Ad...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n TRULANCE® (plecanatide tablets) for Irritable Bowel Syndrome with Constipation in Adults is now Available to Canadians to Help Meet Treatment Gap that leaves 70 Per cent of Patients Unsatisfied(1)\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnrbrb1{\nBORDER-RIGHT:black 1pt\n}\n.prnsblb1{\nBORDER-LEFT:black 1pt\n}\n.prnsbbb1{\nBORDER-BOTTOM:black 1pt\n}\n.prnsbtb1{\nBORDER-TOP:black 1pt\n}\n.prnml4{\nMARGIN-LEFT:0.33em; MARGIN-TOP:0em; MARGIN-BOTTOM:0em\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n LAVAL, QC\n \n ,\n \n Feb. 8, 2022\n \n /CNW Telbec/ - Bausch Health,\n \n Canada\n \n , part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), (\"Bausch Health\" or the \"Company\") today announced the availability through pharmacies across\n \n Canada\n \n of its new prescription treatment TRULANCE® (plecanatide).\n \n \n \n \n \n \n \n \n \n TRULANCE is approved by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults,\n \n 2\n \n and is the first treatment brought to market in\n \n Canada\n \n by the gastrointestinal division of the Company. Canadian treatment guidelines for IBS-C recommend a variety of non-pharmaceutical and pharmaceutical approaches to treatment,\n \n 3\n \n but 70 per cent of surveyed IBS-C patients report no treatment had thus far completely relieved their symptoms.\n \n 4\n \n \n \n \"Bausch Health,\n \n Canada\n \n is proud to launch TRULANCE as the first therapy brought to the Canadian market in an area where there is a great unmet need for Canadian patients and for a condition for which the prevalence in\n \n Canada\n \n is one of the highest in the world,\" said Ginette Gagné, interim president and...